HK1049165A1 - 循環β-氨基酸衍生物作為質基金屬蛋白酶及TNF-α的抑制劑 - Google Patents
循環β-氨基酸衍生物作為質基金屬蛋白酶及TNF-α的抑制劑Info
- Publication number
- HK1049165A1 HK1049165A1 HK03101351.8A HK03101351A HK1049165A1 HK 1049165 A1 HK1049165 A1 HK 1049165A1 HK 03101351 A HK03101351 A HK 03101351A HK 1049165 A1 HK1049165 A1 HK 1049165A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tnf
- inhibitors
- alpha
- amino acid
- acid derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19018200P | 2000-03-17 | 2000-03-17 | |
US23337300P | 2000-09-18 | 2000-09-18 | |
US25553900P | 2000-12-14 | 2000-12-14 | |
PCT/US2001/008334 WO2001070673A2 (en) | 2000-03-17 | 2001-03-15 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1049165A1 true HK1049165A1 (zh) | 2003-05-02 |
Family
ID=27392700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03101351.8A HK1049165A1 (zh) | 2000-03-17 | 2003-02-21 | 循環β-氨基酸衍生物作為質基金屬蛋白酶及TNF-α的抑制劑 |
Country Status (20)
Country | Link |
---|---|
US (2) | US6743807B2 (zh) |
EP (1) | EP1263755A2 (zh) |
JP (1) | JP2003528072A (zh) |
KR (1) | KR20030009391A (zh) |
CN (1) | CN1481377A (zh) |
AR (1) | AR035710A1 (zh) |
AU (1) | AU2001250849A1 (zh) |
BR (1) | BR0109467A (zh) |
CA (1) | CA2401870A1 (zh) |
CZ (1) | CZ20023033A3 (zh) |
EE (1) | EE200200529A (zh) |
HK (1) | HK1049165A1 (zh) |
HU (1) | HUP0300850A2 (zh) |
IL (1) | IL151552A0 (zh) |
MX (1) | MXPA02009020A (zh) |
NO (1) | NO20024402D0 (zh) |
NZ (1) | NZ521248A (zh) |
PL (1) | PL360678A1 (zh) |
SK (1) | SK13072002A3 (zh) |
WO (1) | WO2001070673A2 (zh) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4078074B2 (ja) | 1999-12-10 | 2008-04-23 | ファイザー・プロダクツ・インク | ピロロ[2,3−d]ピリミジン化合物 |
CA2439539A1 (en) * | 2001-03-15 | 2002-09-26 | Matthew E. Voss | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage) |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1427408A4 (en) | 2001-09-17 | 2005-10-26 | Bristol Myers Squibb Co | CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM) |
AR040336A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
WO2004022536A1 (en) * | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
US6835841B2 (en) | 2002-09-13 | 2004-12-28 | Bristol-Myers Squibb Company | Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters |
WO2004037805A1 (en) | 2002-10-23 | 2004-05-06 | Glenmark Pharmaceuticals Ltd. | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
PL377791A1 (pl) | 2002-11-21 | 2006-02-20 | Pfizer Products Inc. | Pochodne 3-aminopiperydyny i sposoby ich wytwarzania |
DK1620429T3 (da) | 2003-04-11 | 2009-05-18 | Glenmark Pharmaceuticals Sa | Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse |
ES2563304T3 (es) | 2003-04-24 | 2016-03-14 | Incyte Holdings Corporation | Derivados azaespiro alcano como inhibidores de metaloproteasas |
WO2004099165A2 (en) * | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds and hydro isomers thereof |
WO2005034870A2 (en) | 2003-10-07 | 2005-04-21 | Renovis, Inc. | Amide compounds and ion channel ligands and uses thereof |
GB2413129A (en) * | 2003-10-07 | 2005-10-19 | Renovis Inc | Aromatic amide compounds as ion channel ligands and uses thereof |
EP1678167A1 (en) | 2003-10-17 | 2006-07-12 | Incyte Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
CA2552279C (en) * | 2003-12-02 | 2014-07-15 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors |
AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
EA011402B1 (ru) | 2004-01-23 | 2009-02-27 | Эмджен Инк. | Азотсодержащие гетероциклические производные и их фармацевтические применения |
US7514434B2 (en) | 2004-02-23 | 2009-04-07 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof |
EA011764B1 (ru) | 2004-03-05 | 2009-06-30 | Ниссан Кемикал Индастриз, Лтд. | Изоксазолинзамещённое производное бензамида и пестицид |
US7683097B2 (en) * | 2004-05-27 | 2010-03-23 | Propharmacon Inc. | Topoisomerase inhibitors |
US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
BRPI0516341A (pt) | 2004-10-13 | 2008-09-02 | Glenmark Pharmaceuticals Sa | método para preparação de intermediários de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida, método para a preparação de compostos intermediários de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida, n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzeno [b,d] furano-1-carboxamida, método para a sìntese de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida e seu sal sódico de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida |
MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
ZA200704789B (en) * | 2004-12-07 | 2008-11-26 | Toyoma Chemical Co Ltd | Novel anthranilic acid derivative or salt thereof |
MX2007007345A (es) | 2004-12-17 | 2007-09-07 | Glenmark Pharmaceuticals Sa | Compuestos heterociclicos novedosos utiles para el tratamiento de trastornos inflamatorios y alergicos. |
SI1831227T1 (sl) | 2004-12-17 | 2013-09-30 | Glenmark Pharmaceuticals S.A. | Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj |
US7595327B2 (en) | 2005-03-21 | 2009-09-29 | Wyeth | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase |
GB0505969D0 (en) | 2005-03-23 | 2005-04-27 | Novartis Ag | Organic compounds |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
WO2006123762A1 (ja) * | 2005-05-16 | 2006-11-23 | Sumitomo Chemical Company, Limited | ピロリジン化合物の製造方法 |
GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
WO2007049728A1 (en) * | 2005-10-27 | 2007-05-03 | Sumitomo Chemical Company, Limited | Amide compounds and their use |
WO2007053495A2 (en) * | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
US8067415B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
PT2420491E (pt) | 2005-12-30 | 2013-10-14 | Novartis Ag | Compostos de piperidina 3,5-substituída como inibidores de renina |
US7968708B2 (en) * | 2006-12-06 | 2011-06-28 | The Research Foundation Of State University Of New York | Azepans and methods for making and using same |
JP5206993B2 (ja) | 2007-03-07 | 2013-06-12 | 日産化学工業株式会社 | イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤 |
ES2541107T3 (es) | 2007-06-25 | 2015-07-16 | Novartis Ag | Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidindicarboxamida para su uso como inhibidores de renina |
US8278313B2 (en) | 2008-03-11 | 2012-10-02 | Abbott Laboratories | Macrocyclic spiro pyrimidine derivatives |
US8436005B2 (en) | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
JP2011524893A (ja) | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
US20120115907A1 (en) * | 2009-04-24 | 2012-05-10 | Cadila Healthcare Limited | Novel compounds as inhibitors of renin |
ES2711936T3 (es) | 2009-09-04 | 2019-05-08 | Biogen Ma Inc | Inhibidores de la tirosina cinasa de Bruton |
EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
WO2012060884A1 (en) * | 2010-11-04 | 2012-05-10 | Nestec S.A. | Methods and compositions for preventing and treating osteoarthritis |
WO2012079154A1 (en) * | 2010-12-14 | 2012-06-21 | Dalhousie University | Selective estrogen receptor modulators |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
EP2684865A1 (en) * | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
KR102365952B1 (ko) | 2013-10-14 | 2022-02-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
EP3057964B1 (en) | 2013-10-14 | 2019-12-04 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
ES2838573T3 (es) * | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Derivados de benzamida ligados como inhibidores potentes de ROCK |
AU2017298035B2 (en) | 2016-07-21 | 2021-10-28 | Biogen Ma Inc. | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors |
AU2019352741A1 (en) | 2018-10-04 | 2021-05-06 | Assistance Publique-Hôpitaux De Paris (Aphp) | EGFR inhibitors for treating keratodermas |
KR102614653B1 (ko) * | 2021-06-09 | 2023-12-20 | 한국과학기술연구원 | 신규한 헤테로사이클릴-페닐-메틸아민 유도체, 이의 제조방법 및 이의 다발성 경화증 예방, 개선, 또는 치료 용도 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212182A (en) * | 1990-10-03 | 1993-05-18 | American Home Products Corpooration | Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics |
AU725831C (en) | 1995-12-08 | 2002-10-17 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
JP3541043B2 (ja) * | 1996-08-28 | 2004-07-07 | ザ プロクター アンド ギャンブル カンパニー | 置換環状アミンメタロプロテアーゼ阻害剤 |
US6420427B1 (en) * | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
US6569899B1 (en) * | 1999-04-06 | 2003-05-27 | Ono Pharmaceuticals Co., Ltd. | 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient |
AU4249700A (en) * | 1999-04-19 | 2000-11-02 | Sumitomo Pharmaceuticals Company, Limited | Hydroxamic acid derivative |
AUPP982399A0 (en) | 1999-04-19 | 1999-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Mmp inhibitor |
-
2001
- 2001-03-15 KR KR1020027012253A patent/KR20030009391A/ko not_active Application Discontinuation
- 2001-03-15 IL IL15155201A patent/IL151552A0/xx unknown
- 2001-03-15 EP EP01924170A patent/EP1263755A2/en not_active Withdrawn
- 2001-03-15 HU HU0300850A patent/HUP0300850A2/hu unknown
- 2001-03-15 SK SK1307-2002A patent/SK13072002A3/sk unknown
- 2001-03-15 WO PCT/US2001/008334 patent/WO2001070673A2/en not_active Application Discontinuation
- 2001-03-15 CZ CZ20023033A patent/CZ20023033A3/cs unknown
- 2001-03-15 BR BR0109467-0A patent/BR0109467A/pt not_active Application Discontinuation
- 2001-03-15 JP JP2001568885A patent/JP2003528072A/ja active Pending
- 2001-03-15 CN CNA018094090A patent/CN1481377A/zh active Pending
- 2001-03-15 AU AU2001250849A patent/AU2001250849A1/en not_active Abandoned
- 2001-03-15 MX MXPA02009020A patent/MXPA02009020A/es unknown
- 2001-03-15 CA CA002401870A patent/CA2401870A1/en not_active Abandoned
- 2001-03-15 NZ NZ521248A patent/NZ521248A/en unknown
- 2001-03-15 EE EEP200200529A patent/EE200200529A/xx unknown
- 2001-03-15 PL PL36067801A patent/PL360678A1/xx not_active Application Discontinuation
- 2001-03-16 US US09/811,233 patent/US6743807B2/en not_active Expired - Lifetime
- 2001-03-16 AR ARP010101254A patent/AR035710A1/es unknown
-
2002
- 2002-09-13 NO NO20024402A patent/NO20024402D0/no unknown
-
2003
- 2003-02-21 HK HK03101351.8A patent/HK1049165A1/zh unknown
-
2004
- 2004-02-13 US US10/779,539 patent/US6984648B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
BR0109467A (pt) | 2003-06-03 |
MXPA02009020A (es) | 2003-02-12 |
AU2001250849A1 (en) | 2001-10-03 |
EE200200529A (et) | 2004-02-16 |
US20020016336A1 (en) | 2002-02-07 |
KR20030009391A (ko) | 2003-01-29 |
AR035710A1 (es) | 2004-07-07 |
NZ521248A (en) | 2004-04-30 |
IL151552A0 (en) | 2003-04-10 |
HUP0300850A2 (hu) | 2003-07-28 |
CN1481377A (zh) | 2004-03-10 |
US6984648B2 (en) | 2006-01-10 |
CA2401870A1 (en) | 2001-09-27 |
PL360678A1 (en) | 2004-09-20 |
US20040162426A1 (en) | 2004-08-19 |
US6743807B2 (en) | 2004-06-01 |
CZ20023033A3 (cs) | 2003-01-15 |
EP1263755A2 (en) | 2002-12-11 |
JP2003528072A (ja) | 2003-09-24 |
SK13072002A3 (sk) | 2003-08-05 |
WO2001070673A3 (en) | 2002-03-14 |
NO20024402D0 (no) | 2002-09-13 |
WO2001070673A2 (en) | 2001-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL151552A0 (en) | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha | |
IL151018A0 (en) | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha | |
AU4180900A (en) | Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase | |
IL156096A0 (en) | New mandelic acid derivatives and their use as thrombin inhibitors | |
HUP0304052A3 (en) | Heterocyclic inhibitors of erk2 and uses thereof | |
IL154841A0 (en) | 2-amino-2-alkyl-5- heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | |
HK1057539A1 (en) | Beta-amino acid nitrile derivatives | |
HUP0201846A2 (en) | Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them | |
AU2003261319A8 (en) | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme | |
HK1045501A1 (zh) | 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物 | |
AU2003301903A8 (en) | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme | |
NZ513701A (en) | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors | |
AU2002246983A1 (en) | 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha | |
PL357084A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
EP1373199A4 (en) | SPIROCYCLIC BETA-AMINOACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND THE CONVERSION ENZYME OF TNF-ALPHA (TAGE) | |
IL164267A0 (en) | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | |
HK1063627A1 (en) | New mandelic acid derivative and its use as thrombin inhibitors | |
IL156775A0 (en) | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | |
EP1282694A4 (en) | AMINO ACID DERIVATIVES OF SULFAMIDE AND BIS-SULFAMIDE AS INHIBITORS OF PROTEOLYTIC ENZYMES | |
EP1493819A4 (en) | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND ACID ESTER OPTICALLY ACTIVE 2-HOMOPIPECOLIC N-SUBSTITUTED | |
AU2003228701A1 (en) | Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases | |
AU5366301A (en) | Methods of treating plants with glycolic acid | |
GB0026610D0 (en) | Diaminocyclobutenediones as inhibitors of IMPDH enzyme | |
KR20020006643A (en) | Rosmarinic acid derivatives as an immunosuppressant and an inhibitor of sh2 | |
NO20001447D0 (no) | Modifisert polyasparginsyre og fremgangsmåte for produksjon og bruk derav |